Developing a preference-based utility scoring algorithm for the Psoriasis Area Severity Index (PASI)

References

• Brazier JR, Ratcliffe J, Salomon JA, et al. Measuring and valuing health benefits for economic evaluation. New York, NY: Oxford University Press; 2007.
   Google Scholar
• Feeny D. Preference-based measures: utility and quality-adjusted life years. In: Fayers P, Hays R, editors. Assessing quality of life in clinical trials. 2nd ed. New York, NY: Oxford University Press; 2005. p. 405–431.
   Google Scholar
• Torrance GW. Measurement of health state utilities for economic appraisal. J Health Econ. 1986;5:1–30.
   PubMed Web of Science ®Google Scholar
• Brazier JE, Rowen D, Mavranezouli I, et al. Developing and testing methods for deriving preference-based measures of health from condition-specific measures (and other patient-based measures of outcome). Health Technol Assess. 2012;16:1–114.
   Web of Science ®Google Scholar
• Yang Y, Brazier J, Longworth L. EQ-5D in skin conditions: an assessment of validity and responsiveness. Eur J Health Econ. 2015;16:927–939.
   Web of Science ®Google Scholar
• Pereira FR, Basra MK, Finlay AY, et al. The role of the EQ-5D in the economic evaluation of dermatological conditions and therapies. Dermatology. 2012;225:45–53.
   PubMed Web of Science ®Google Scholar
• Pickard AS, Gooderham M, Hartz S, et al. EQ-5D health utilities: exploring ways to improve upon responsiveness in psoriasis. J Med Econ. 2017;20:19–27.
   PubMed Web of Science ®Google Scholar
• Swinburn P, Lloyd A, Boye KS, et al. Development of a disease-specific version of the EQ-5D-5L for use in patients suffering from psoriasis: lessons learned from a feasibility study in the UK. Value Health. 2013;16:1156–1162.
   PubMed Web of Science ®Google Scholar
• Lebwohl M. Psoriasis. Lancet. 2003;361:1197–1204.
   PubMed Web of Science ®Google Scholar
• Blome C, Beikert FC, Rustenbach SJ, et al. Mapping DLQI on EQ-5D in psoriasis: transformation of skin-specific health-related quality of life into utilities. Arch Dermatol Res. 2013;305:197–204.
   PubMed Web of Science ®Google Scholar
• Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19:210–216.
   PubMed Web of Science ®Google Scholar
• Feldman SR, Krueger GG. Psoriasis assessment tools in clinical trials. Ann Rheum Dis. 2005;64: ii65–ii68.
   PubMed Web of Science ®Google Scholar
• Fredriksson T, Pettersson U. Severe psoriasis-oral therapy with a new retinoid. Dermatologica. 1978;157:238–244.
   PubMedGoogle Scholar
• Gaspari AA, Tyring SK. Commonly applied clinical trial endpoints for psoriasis and PsA. Clinical and basic immunodermatology. London, UK: Springer; 2008. p. 526.
   Google Scholar
• Navarini AA, Poulin Y, Menter A, et al. Analysis of body regions and components of PASI scores during adalimumab or methotrexate treatment for patients with moderate-to-severe psoriasis. J Drugs Dermatol. 2014;13:554–562.
   PubMed Web of Science ®Google Scholar
• Spuls PI, Lecluse LL, Poulsen ML, et al. How good are clinical severity and outcome measures for psoriasis?: quantitative evaluation in a systematic review. J Invest Dermatol. 2010;130:933–943.
   PubMed Web of Science ®Google Scholar
• Mavranezouli I, Brazier JE, Rowen D, et al. Estimating a preference-based index from the Clinical Outcomes in Routine Evaluation-Outcome Measure (CORE-OM): valuation of CORE-6D. Med Decis Making. 2013;33:381–395.
   PubMed Web of Science ®Google Scholar
• Rentz AM, Kowalski JW, Walt JG, et al. Development of a preference-based index from the National Eye Institute Visual Function Questionnaire-25. JAMA Ophthalmol. 2014;132:310.
   PubMed Web of Science ®Google Scholar
• Yang Y, Brazier J, Tsuchiya A, et al. Estimating a preference-based single index from the Overactive Bladder Questionnaire. Value Health. 2009;12:159–166.
   PubMed Web of Science ®Google Scholar
• Yang Y, Brazier JE, Tsuchiya A, et al. Estimating a preference-based index for a 5-dimensional health state classification for asthma derived from the asthma quality of life questionnaire. Med Decis Making. 2011;31:281–291.
   PubMed Web of Science ®Google Scholar
• Papp KA, Leonardi C, Menter A, et al. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med. 2012;366:1181–1189.
   PubMed Web of Science ®Google Scholar
• CADTH (Canadian Agency for Drugs and Technologies in Health). Guidelines for the economic evaluation of health technologies: Canada. 3rd ed. Ottawa, Canada: Canadian Agency for Drugs and Technologies in Health; 2006.
   Google Scholar
• NICE (National Institute for Health and Care Excellence). Process and methods guides: Guide to the methods of technology appraisal 2013. London, UK: NICE; 2013.
   Google Scholar
• PBAC (Pharmaceutical Benefits Advisory Committee). Guidelines for preparing submissions to PBAC, Version 4.4. Canberra, Australia: Australian Government Department of Health, PBAC; 2013. p. 344.
   Google Scholar
• Matza LS, Sapra SJ, Dillon JF, et al. Health state utilities associated with attributes of treatments for hepatitis C. Eur J Health Econ. 2015;16:1005–1018.
   PubMed Web of Science ®Google Scholar
• Rowen D, Brazier J. Health utility measurement. In: Glied S, Smith P, editors. The Oxford Handbook of Health Economics. New York: Oxford University Press; 2011. p. 788–813.
   Google Scholar
• Brazier J, Czoski-Murray C, Roberts J, et al. Estimation of a preference-based index from a condition-specific measure: the King's Health Questionnaire. Med Decis Making. 2008;28:113–126.
   PubMed Web of Science ®Google Scholar
• Ryan TP. Modern regression methods. 2nd ed. Hoboken, NJ: John Wiley & Sons, Inc.; 2009.
   Google Scholar
• Versteegh MM, Leunis A, Uyl-de Groot CA, et al. Condition-specific preference-based measures: benefit or burden? Value Health. 2012;15:504–513.
   PubMed Web of Science ®Google Scholar